In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4231-4239

  Makobongo, Morris O ^a   Kovachi, Tchelet ^b   Gancz, Hanan ^a   Mor, Amram ^b   Merrell, D Scott ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; DODECANOIC ACID 2 LYSYL AMINODODECANOYL LYSINE; DODECANOIC ACID LYSINE 2 LYSYL AMINODODECANOYL LYSINE; DODECANOIC ACID LYSINE 5 AMINOOCTANOYL LYSINE; DODECANOIC ACID LYSINE 7 AMINOOCTANOYL LYSINE; LYSYL AMINODODECANOYL LYSINE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL KINETICS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG STABILITY; GROWTH INHIBITION; HELICOBACTER PYLORI; HIGH TEMPERATURE; IN VITRO STUDY; INCUBATION TIME; LIQUID CULTURE; LOW TEMPERATURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; HELICOBACTER PYLORI; HEMOLYSIS; HORSES; HYDROGEN-ION CONCENTRATION; KINETICS; MICROBIAL SENSITIVITY TESTS; POLYMERS; TEMPERATURE;

EID: 70349330342     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00510-09     Document Type: Article

References (81)

1. Alm, R. A., L. S. Ling, D. T. Moir, B. L. King, E. D. Brown, P. C. Doig, D. R. Smith, B. Noonan, B. C. Guild, B. L. deJonge, G. Carmel, P. J. Tummino, A. Caruso, M. Uria-Nickelsen, D. M. Mills, C. Ives, R. Gibson, D. Merberg, S. D. Mills, Q. Jiang, D. E. Taylor, G. F. Vovis, and T. J. Trust. 1999. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397:176-180.
2. Andra, J., D. Monreal, G. Martinez de Tejada, C. Olak, G. Brezesinski, S. S. Gomez, T. Goldmann, R. Bartels, K. Brandenburg, and I. Moriyon. 2007. Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against Gram-negative pathogens. J. Biol. Chem. 282:14719-14728.
3. Baltrus, D. A., M. R. Amieva, A. Covacci, T. M. Lowe, D. S. Merrell, K. M. Ottemann, M. Stein, N. R. Salama, and K. Guillemin. 2009. The complete genome sequence of Helicobacter pylori strain G27. J. Bacteriol. 191:447-448.
4. Banemann, A., H. Deppisch, and R. Gross. 1998. The lipopolysaccharide of Bordetella bronchiseptica acts as a protective shield against antimicrobial peptides. Infect. Immun. 66:5607-5612.
5. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3:238-250.
6. Calvet, X., M. Lopez-Lorente, M. Cubells, M. Bare, E. Galvez, and E. Molina. 1999. Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. Aliment. Pharmacol. Ther. 13:781-786.
7. Chan, D. I., E. J. Prenner, and H. J. Vogel. 2006. Tryptophan- and argininerich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta 1758:1184-1202.
8. Cheng, H., and F. L. Hu. 2009. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J. Gastroenterol. 15:860-864.
9. Chey, W. D., and B. C. Wong. 2007. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 102:1808-1825.
10. Clausell, A., M. Garcia-Subirats, M. Pujol, M. A. Busquets, F. Rabanal, and Y. Cajal. 2007. Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J. Phys. Chem. B 111:551-563.
11. Comet, R., X. Calvet, M. Navarro, N. Garcia, and I. Sanfeliu. 1998. Sevenday omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection. Gastroenterol. Hepatol. 21:81-83. (In Spanish.)
12. Cozens, R. M., E. Tuomanen, W. Tosch, O. Zak, J. Suter, and A. Tomasz. 1986. Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat. Antimicrob. Agents Chemother. 29:797-802.
13. de Boer, W. A., R. J. van Etten, R. W. Schade, M. E. Ouwehand, P. M. Schneeberger, and G. N. Tytgat. 1996. 4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection. Am. J. Gastroenterol. 91:1778-1782.
14. Della Monica, P., A. Lavagna, G. Masoero, L. Lombardo, L. Crocella, and A. Pera. 2002. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment. Pharmacol. Ther. 16:1269-1275.
15. Epand, R. M., S. Rotem, A. Mor, B. Berno, and R. F. Epand. 2008. Bacterial membranes as predictors of antimicrobial potency. J. Am. Chem. Soc. 130: 14346-14352.
16. Epand, R. M., and H. J. Vogel. 1999. Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophys. Acta 1462:11-28.
17. Eudy, W. W., and S. E. Burrous. 1973. Generation times of Proteus mirabilis and Escherichia coli in experimental infections. Chemotherapy 19:161-170.
18. Felga, G. E., F. M. Silva, R. C. Barbuti, T. Navarro-Rodriguez, S. Zaterka, and J. N. Eisig. 2008. Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. World J. Gastroenterol. 14:6224-6227.
19. Fennerty, M. B., D. A. Lieberman, N. Vakil, N. Magaret, D. O. Faigel, and M. Helfand. 1999. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch. Intern. Med. 159:1562-1566.
20. Franco, A. T., D. A. Israel, M. K. Washington, U. Krishna, J. G. Fox, A. B. Rogers, A. S. Neish, L. Collier-Hyams, G. I. Perez-Perez, M. Hatakeyama, R. Whitehead, K. Gaus, D. P. O'Brien, J. Romero-Gallo, and R. M. Peek, Jr. 2005. Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc. Natl. Acad. Sci. USA 102:10646-10651.
21. Gisbert, J. P., J. L. Gisbert, S. Marcos, I. Jimenez-Alonso, R. Moreno-Otero, and J. M. Pajares. 2008. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment. Pharmacol. Ther. 27:346-354.
22. Gisbert, J. P., L. Gonzalez, X. Calvet, N. Garcia, T. Lopez, M. Roque, R. Gabriel, and J. M. Pajares. 2000. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment. Pharmacol. Ther. 14:1319-1328.
23. Gisbert, J. P., S. Marcos, J. L. Gisbert, and J. M. Pajares. 2001. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur. J. Gastroenterol. Hepatol. 13:1303-1307.
24. Gisbert, J. P., R. Pajares, and J. M. Pajares. 2007. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 12(Suppl. 2):50-58.
25. Glukhov, E., M. Stark, L. L. Burrows, and C. M. Deber. 2005. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J. Biol. Chem. 280:33960-33967.
26. Glupczynski, Y., F. Megraud, M. Lopez-Brea, and L. P. Andersen. 2001. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 20:820-823.
27. Goldman, R. C., D. Zakula, R. Flamm, J. Beyer, and J. Capobianco. 1994. Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob. Agents Chemother. 38: 1496-1500.
28. Goodwin, A., D. Kersulyte, G. Sisson, S. J. Veldhuyzen van Zanten, D. E. Berg, and P. S. Hoffman. 1998. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 28:383-393.
29. Gudmundsson, S., S. Einarsson, H. Erlendsdottir, J. Moffat, W. Bayer, and W. A. Craig. 1993. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. J. Antimicrob. Chemother. 31(Suppl D):177-191.
30. Haine, E. R., Y. Moret, M. T. Siva-Jothy, and J. Rolff. 2008. Antimicrobial defense and persistent infection in insects. Science 322:1257-1259.
31. Hassan, I. J., R. M. Stark, J. Greenman, and M. R. Millar. 1998. Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637. J. Antimicrob. Chemother. 42:661-663.
32. Heep, M., M. Kist, S. Strobel, D. Beck, and N. Lehn. 2000. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur. J. Clin. Microbiol. Infect. Dis. 19:538-541.
33. Hoffman, P. S., A. Goodwin, J. Johnsen, K. Magee, and S. J. Veldhuyzen van Zanten. 1996. Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J. Bacteriol. 178:4822-4829.
34. Howden, C. W., and R. H. Hunt. 1998. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol. 93:2330-2338.
35. Iacopini, F., P. Crispino, O. A. Paoluzi, A. Consolazio, R. Pica, M. Rivera, D. Palladini, F. Nardi, and P. Paoluzi. 2005. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig. Liver Dis. 37:571-576.
36. Jafri, N. S., C. A. Hornung, and C. W. Howden. 2008. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann. Intern. Med. 148:923-931.
37. Janssen, M. J., A. H. Van Oijen, A. L. Verbeek, J. B. Jansen, and W. A. De Boer. 2001. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment. Pharmacol. Ther. 15:613-624.
38. Jones, K. R., J.-H. Cha, and D. S. Merrell. 2008. Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori. Curr. Drug Ther. 3:190-203.
39. Jorgensen, M. A., J. Manos, G. L. Mendz, and S. L. Hazell. 1998. The mode of action of metronidazole in Helicobacter pylori: futile cycling or reduction? J. Antimicrob. Chemother. 41:67-75.
40. Kuo, C. H., H. M. Hu, F. C. Kuo, P. I. Hsu, A. Chen, F. J. Yu, P. Y. Tsai, I. C. Wu, S. W. Wang, C. J. Li, B. C. Weng, L. L. Chang, C. M. Jan, W. M. Wang, and D. C. Wu. 2009. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J. Antimicrob. Chemother. 63:1017-1024.
41. Kwon, D. H., M. Kato, F. A. El-Zaatari, M. S. Osato, and D. Y. Graham. 2000. Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance. FEMS Microbiol. Lett. 188:197-202.
42. Lai, R., Y. T. Zheng, J. H. Shen, G. J. Liu, H. Liu, W. H. Lee, S. Z. Tang, and Y. Zhang. 2002. Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima. Peptides 23:427-435. (Pubitemid 34143258)
43. Lee, A., J. O'Rourke, M. C. De Ungria, B. Robertson, G. Daskalopoulos, and M. F. Dixon. 1997. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112:1386-1397.
44. Malfertheiner, P., F. Megraud, C. O'Morain, F. Bazzoli, E. El-Omar, D. Graham, R. Hunt, T. Rokkas, N. Vakil, and E. J. Kuipers. 2007. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56:772-781.
45. Marki, F., E. Hanni, A. Fredenhagen, and J. van Oostrum. 1991. Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2. Biochem. Pharmacol. 42:2027-2035.
46. Marshall, B. J., J. R. Warren, D. B. McGechie, G. J. Francis, P. J. Utley, P. A. Rogers, and R. J. Glancy. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet i:1311-1315.
47. Matsuhisa, T., T. Kawai, T. Masaoka, H. Suzuki, M. Ito, Y. Kawamura, K. Tokunaga, M. Suzuki, T. Mine, S. Takahashi, and N. Sakaki. 2006. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area. Helicobacter 11:152-158.
48. Maw, J., and G. G. Meynell. 1968. The true division and death rates of Salmonella typhimurium in the mouse spleen determined with superinfecting phage P22. Br. J. Exp. Pathol. 49:597-613.
49. McMahon, B. J., T. W. Hennessy, J. M. Bensler, D. L. Bruden, A. J. Parkinson, J. M. Morris, A. L. Reasonover, D. A. Hurlburt, M. G. Bruce, F. Sacco, and J. C. Butler. 2003. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann. Intern. Med. 139:463-469.
50. Megraud, F., and H. Lamouliatte. 2003. Review article: the treatment of refractory Helicobacter pylori infection. Aliment. Pharmacol. Ther. 17:1333-1343.
51. Miehlke, S., W. Schneider-Brachert, C. Kirsch, A. Morgner, A. Madisch, E. Kuhlisch, C. Haferland, E. Bastlein, C. Jebens, C. Zekorn, H. Knoth, M. Stolte, and N. Lehn. 2008. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 13: 69-74.
52. Mobley, H. L., M. J. Cortesia, L. E. Rosenthal, and B. D. Jones. 1988. Characterization of urease from Campylobacter pylori. J. Clin. Microbiol. 26:831-836.
53. Nan, Y. H., K. H. Park, Y. Park, Y. J. Jeon, Y. Kim, I. S. Park, K. S. Hahm, and S. Y. Shin. 2009. Investigating the effects of positive charge and hydrophobicity on the cell selectivity, mechanism of action and anti-inflammatory activity of a Trp-rich antimicrobial peptide indolicidin. FEMS Microbiol. Lett. 292:134-140.
54. Navon-Venezia, S., R. Feder, L. Gaidukov, Y. Carmeli, and A. Mor. 2002. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob. Agents Chemother. 46:689-694.
55. Nomura, A., G. N. Stemmermann, P. H. Chyou, I. Kato, G. I. Perez-Perez, and M. J. Blaser. 1991. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N. Engl. J. Med. 325:1132-1136.
56. Nomura, A., G. N. Stemmermann, P. H. Chyou, G. I. Perez-Perez, and M. J. Blaser. 1994. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann. Intern. Med. 120:977-981.
57. Oh, J. D., H. Kling-Backhed, M. Giannakis, J. Xu, R. S. Fulton, L. A. Fulton, H. S. Cordum, C. Wang, G. Elliott, J. Edwards, E. R. Mardis, L. G. Engstrand, and J. I. Gordon. 2006. The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression. Proc. Natl. Acad. Sci. USA 103:9999-10004.
58. Owen, R. J., S. R. Martin, and P. Borman. 1985. Rapid urea hydrolysis by gastric campylobacters. Lancet i:111.
59. Paoluzi, P., F. Iacopini, P. Crispino, F. Nardi, A. Bella, M. Rivera, P. Rossi, M. Gurnari, F. Caracciolo, M. Zippi, and R. Pica. 2006. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter 11:562-568.
60. Parsonnet, J., S. Hansen, L. Rodriguez, A. B. Gelb, R. A. Warnke, E. Jellum, N. Orentreich, J. H. Vogelman, and G. D. Friedman. 1994. Helicobacter pylori infection and gastric lymphoma. N. Engl. J. Med. 330:1267-1271.
61. Radzishevsky, I., M. Krugliak, H. Ginsburg, and A. Mor. 2007. Antiplasmodial activity of lauryl-lysine oligomers. Antimicrob. Agents Chemother. 51: 1753-1759.
62. Radzishevsky, I. S., T. Kovachi, Y. Porat, L. Ziserman, F. Zaknoon, D. Danino, and A. Mor. 2008. Structure-activity relationships of antibacterial acyl-lysine oligomers. Chem. Biol. 15:354-362.
63. Radzishevsky, I. S., S. Rotem, D. Bourdetsky, S. Navon-Venezia, Y. Carmeli, and A. Mor. 2007. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat. Biotechnol. 25:657-659.
64. Rotem, S., I. S. Radzishevsky, D. Bourdetsky, S. Navon-Venezia, Y. Carmeli, and A. Mor. 2008. Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J. 22:2652-2661.
65. Sarig, H., S. Rotem, L. Ziserman, D. Danino, and A. Mor. 2008. Impact of self-assembly properties on antibacterial activity of short acyl-lysine oligomers. Antimicrob. Agents Chemother. 52:4308-4314.
66. Schibli, D. J., R. F. Epand, H. J. Vogel, and R. M. Epand. 2002. Tryptophanrich antimicrobial peptides: comparative properties and membrane interactions. Biochem. Cell Biol. 80:667-677.
67. Scott, D. R., E. A. Marcus, D. L. Weeks, and G. Sachs. 2002. Mechanisms of acid resistance due to the urease system of Helicobacter pylori. Gastroenterology 123:187-195.
68. Scott, D. R., D. Weeks, C. Hong, S. Postius, K. Melchers, and G. Sachs. 1998. The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 114:58-70.
69. Shai, Y. 1999. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell nonselective membrane-lytic peptides. Biochim. Biophys. Acta 1462:55-70.
70. Sorberg, M., H. Hanberger, M. Nilsson, and L. E. Nilsson. 1997. Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori. Antimicrob. Agents Chemother. 41:2218-2223.
71. Stratton, C. W., K. E. Aldridge, and M. S. Gelfand. 1995. In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels. Diagn. Microbiol. Infect. Dis. 22:35-42.
72. Tomb, J. F., O. White, A. R. Kerlavage, R. A. Clayton, G. G. Sutton, R. D. Fleischmann, K. A. Ketchum, H. P. Klenk, S. Gill, B. A. Dougherty, K. Nelson, J. Quackenbush, L. Zhou, E. F. Kirkness, S. Peterson, B. Loftus, D. Richardson, R. Dodson, H. G. Khalak, A. Glodek, K. McKenney, L. M. Fitzegerald, N. Lee, M. D. Adams, E. K. Hickey, D. E. Berg, J. D. Gocayne, T. R. Utterback, J. D. Peterson, J. M. Kelley, M. D. Cotton, J. M. Weidman, C. Fujii, C. Bowman, L. Watthey, E. Wallin, W. S. Hayes, M. Borodovsky, P. D. Karp, H. O. Smith, C. M. Fraser, and J. C. Venter. 1997. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388: 539-547.
73. Vaira, D., A. Zullo, N. Vakil, L. Gatta, C. Ricci, F. Perna, C. Hassan, V. Bernabucci, A. Tampieri, and S. Morini. 2007. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann. Intern. Med. 146:556-563.
74. Vakil, N., and D. Vaira. 2008. Sequential therapy for Helicobacter pylori: time to consider making the switch? JAMA 300:1346-1347.
75. Vanhoye, D., F. Bruston, P. Nicolas, and M. Amiche. 2003. Antimicrobial peptides from hylid and ranin frogs originated from a 150-million-year-old ancestral precursor with a conserved signal peptide but a hypermutable antimicrobial domain. Eur. J. Biochem. 270:2068-2081.
76. van Kraaij, C., E. Breukink, M. A. Noordermeer, R. A. Demel, R. J. Siezen, O. P. Kuipers, and B. de Kruijff. 1998. Pore formation by nisin involves translocation of its C-terminal part across the membrane. Biochemistry 37: 16033-16040.
77. van Vliet, A. H., J. Stoof, S. W. Poppelaars, S. Bereswill, G. Homuth, M. Kist, E. J. Kuipers, and J. G. Kusters. 2003. Differential regulation of amidaseand formamidase-mediated ammonia production by the Helicobacter pylori fur repressor. J. Biol. Chem. 278:9052-9057.
78. Wang, W. H., B. C. Wong, A. K. Mukhopadhyay, D. E. Berg, C. H. Cho, K. C. Lai, W. H. Hu, F. M. Fung, W. M. Hui, and S. K. Lam. 2000. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment. Pharmacol. Ther. 14:901-910.
79. Yin, Y., L. H. He, and J. Z. Zhang. 2009. Successful isolation of Helicobacter pylori after prolonged incubation from a patient with failed eradication therapy. World J. Gastroenterol. 15:1528-1529.
80. Zanetti, M. 2005. The role of cathelicidins in the innate host defenses of mammals. Curr. Issues Mol. Biol. 7:179-196.
81. Zullo, A., F. Perna, C. Hassan, C. Ricci, I. Saracino, S. Morini, and D. Vaira. 2007. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment. Pharmacol. Ther. 25:1429-1434.